Benign Prostatic Hyperplasia Treatment Market Will be Led by North America

Posted by Aryan on July 28th, 2023

The benign prostatic hyperplasia treatment market will reach USD 18,837.7 million in 2030, with a CAGR of 5.2% in the years to come. The increasing occurrence of BPH, surging preference for minimally invasive surgeries, and growing investments, funds, and grants for conducting research on novel treatments are the protruding contributors to the development.

The larger share, around 85%, was held by drugs. This is because of the growing requirement for alpha-blockers as these medicines relax the muscle of the prostate and bladder neck, enabling urine flowing more easily.

Amongst the diverse types of drugs, alpha-blockers have been extensively used for treating the disease recently. Their increasing usage and the abundance of medicines under expansion present potential prospects for the industry.

Home healthcare settings had the larger share, and they will record the higher rate, over 5%, in the years to come, as a result of the growing patient count prescribed drugs over surgical treatment.

North America dominated the BPH treatment market with 41% share, as stated by a market research firm, P&S Intelligence. The increasing occurrence of the problem is powering the acceptance of cutting-edge treatments, for example, prostatic stenting, laser therapy, and UroLift therapy, thereby powering the development of the industry in the region.

Download sample pages of this report: https://www.psmarketresearch.com/market-analysis/benign-prostatic-hyperplasia-treatment-bph-market/report-sample

APAC will grow the fastest in the years to come, at a rate of 6.4%. The improving standards of living, increasing per capita income and spending ability, snowballing burden of urological disease, and increasing investment in the healthcare for boosting the progress.

Furthermore, the increasing aging male population, together with a boom in the occurrence of obesity and diabetes, will power the prevalence of BPH and other lower urinary tract conditions.

China, India and Japan together have a large aging male population, requiring regular medical assistance, being extremely susceptible to chronic ailments as a result of its low immunity.

Therefore, patients with an irregular growth of the prostate are needed to be treated, to prevent urethra blockage and decrease the related cancer risk.

The increasing elderly male population is the main reason for the growing demand for BPH treatment all over the world.